Tools for Late-Stage Development

Patient Share Forecasting

For teams in late-stage development, we seamlessly integrate our Competition Module with our DTA technology to forecast patient share over time. Our forecasting models instantly revise patient share and revenue predictions when fresh information arises about an asset’s clinical attributes and launch date, or as new information emerges about competitors — allowing teams to quickly and authoritatively answer management questions about the impact of events.

Epidemiology and Patient Flow Modelling

To support revenue projections, we have well-researched, sourced, and carefully calibrated epidemiology estimates in all our DTA and forecast models. In addition, we also offer incidence-based patient flow models that accurately estimate the number of patients available for treatment at each stage of disease and line of treatment.

Market access

Our market access analytics can be used for both early and late phase agents. We compare the clinical benefit of the drug to its cost, and benchmark those results to a historical data set of launched drugs to identify appropriate analogs.  Our clinical benefit vs. cost metric is strongly predictive of the pricing and market access outlook for new agents. We also have distinctive tools for both early- and late-stage oncology as well as rare diseases.